Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

102.20USD
23 Jan 2015
Change (% chg)

$-1.56 (-1.50%)
Prev Close
$103.76
Open
$102.90
Day's High
$102.92
Day's Low
$101.94
Volume
2,847,447
Avg. Vol
2,467,021
52-wk High
$109.49
52-wk Low
$86.09

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products in virtually all... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $286,069.09
Shares Outstanding(Mil.): 2,799.11
Dividend: 0.70
Yield (%): 2.74

Financials

  JNJ.N Industry Sector
P/E (TTM): 17.93 40.21 40.82
EPS (TTM): 5.70 -- --
ROI: -- 19.07 18.35
ROE: -- 19.85 19.25
Search Stocks

Plaintiffs’ lawyers reject J&J claims of fraud in mesh lawsuits

NEW YORK - Lawyers for thousands of women suing Johnson & Johnson’s Ethicon Inc over transvaginal mesh devices are fighting back against the company’s claim that illegal phone solicitations may have resulted in baseless lawsuits.

23 Jan 2015

Plaintiffs' lawyers reject J&J claims of fraud in mesh lawsuits

NEW YORK, Jan 23 - Lawyers for thousands of women suing Johnson & Johnson's Ethicon Inc over transvaginal mesh devices are fighting back against the company's claim that illegal phone solicitations may have resulted in baseless lawsuits.

23 Jan 2015

New sponsors ready to replace old say beleaguered FIFA

LONDON - FIFA have rejected suggestions that major sponsors were cutting their ties with the organisation because it was a "toxic brand", saying on Friday that they were in advanced negotiations with new sponsors eager to replace the old.

23 Jan 2015

J&J's $7.2 bln claim against Boston Scientific now with U.S. judge

NEW YORK, Jan 21 - For more than eight years, Johnson & Johnson has pursued billions of dollars in damages against Boston Scientific Corp after the latter won a controversial - and ultimately ill-fated - bidding war for device maker Guidant.

22 Jan 2015

Johnson & Johnson's forex warning a sign for rival drugmakers

Jan 20 - Johnson & Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck & Co.

21 Jan 2015

UPDATE 1-Stronger dollar hurts J&J's quarterly sales

Jan 20 - Johnson & Johnson reported lower-than-expected quarterly sales as a stronger dollar offset higher sales of the Band-Aid maker's new drugs and older treatments.

20 Jan 2015

J&J's profit beats estimates on sales of new drugs

Jan 20 - Johnson & Johnson reported a slightly better-than-expected quarterly profit as surging sales of new drugs and mainstay older brands offset weak demand for medical devices and consumer healthcare products.

20 Jan 2015

J&J Ebola vaccine gets 100 million euros to speed development

LONDON - Johnson & Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe's Innovative Medicines Initiative to speed development.

16 Jan 2015

J&J Ebola vaccine gets 100 mln euros to speed development

LONDON, Jan 16 - Johnson & Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe's Innovative Medicines Initiative to speed development.

16 Jan 2015

Depomed to pay $1 billion for J&J pain drug franchise

- Depomed Inc on Thursday said it has agreed to pay $1.05 billion to acquire the U.S. rights to Johnson & Johnson's Nucynta opioid pain drug franchise, giving the smaller company a new flagship product expected to significantly add to revenue and earnings.

16 Jan 2015

Earnings vs. Estimates

Search Stocks